|
β-lactam sterile dry powder injection
Composition:
Each Injection contains:
Cefotaxime......................................................................750
mg
Sulbuactam..................................................................1500
mg
Indications:
Used in surgical prophylaxis, meningitis, skin & soft
tissue infections like cellulitis, chronic suppurative
bacterial otits media, cholecystitis, sexually
transmitted disease, Urinary tract infections,
infections in dialysis unit.
Description:
Cefotaxime sodium, a parenteral cephalosporin
antibiotic, exerts its bactericidal action through
inhibition of bacterial cell wall synthesis. Chemical
structure modifications have enabled this compound to be
resistant to the action of Richmond I, III, IV, and V
beta-lactamase enzymes.
Excellent activity against many gram-negative bacilli,
especially Enterobacteriaceae, has been demonstrated.
Antipseudomonal activity is generally poor, however.
Activity against gram-positive cocci, with the notable
exception of Streptococcus fecalis, is adequate.
Anaerobic activity is variable, particularly against
Clostridia and Bacteroides species. Acute, subacute, and
chronic toxicity studies in animals were generally
unremarkable. No mutagenic effects or reproductive
toxicity have been noted in animals.
In man,
cefotaxime is desacetylated to a microbiologically
active metabolite. Urinary excretion is approximately
50-60% and 15-20% of a dose for the parent compound and
desacetyl metabolite, respectively. The elimination
half-life of cefotaxime is about one hour, with the
total body clearance being approximately twice that of
the renal clearance. Severe renal dysfunction causes a
prolongation of the elimination half-life of cefotaxime
and particularly desacetyl cefotaxime.
A
relatively low degree of protein binding in part
attributes to a wide bodily distribution of cefotaxime.
Cefotaxime is effective in a variety of infectious
processes caused by susceptible organisms. Local
reactions at the injection site and hypersensitivity
phenomena are the most common adverse effects.
Comparative trials attesting to cefotaxime's clinical
utility over other parenteral cephalosporins or
amino-glycosides are very limited. Based on the
available evidence, cefotaxime should be most useful in
combating serious gram-negative infections, because of
its excellent activity against most of these organisms
and its low toxicity profile.
CONTRAINDICATIONS
Bactram
is
contraindicated in patients who have shown
hypersensitivity to cefotaxime sodium or the
cephalosporin group of antibiotics.
Dosage: As per
the physician’s advice.
Presentations:
MRP Retailer Stockiest
108.00 86.40 77.76
| 
